MedTrace Logo

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2013-07-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.

DRUG

Canagliflozin

One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.

DRUG

Sitagliptin

One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.

DRUG

Metformin

The patient's stable dose of metformin background therapy should be continued throughout the study.

DRUG

Pioglitazone

The patient's stable dose of pioglitazone background therapy should be continued throughout the study.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC C. Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-11-30
Completion
2012-07-31

Countries

  • United States
  • Canada
  • Finland
  • France
  • Germany
  • Greece
  • India
  • Mexico
  • Spain
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106690 on ClinicalTrials.gov